The Company, in consultation with its outside counsel, is currently evaluating its options and next steps.
VANCOUVER, British Columbia, Nov. 21, 2017 (GLOBE NEWSWIRE) -- Novelion (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare metabolic diseases, today announced that District Judge William Young rejected Aegerion Pharmaceuticals’ amended criminal plea agreement which was negotiated with the United States Department of Justice (DOJ). Aegerion Pharmaceuticals is an indirect subsidiary of Novelion. The Company, in consultation with its outside counsel, is currently evaluating its options and next steps.
About Novelion Therapeutics
Novelion Therapeutics is a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases. Novelion has a diversified commercial portfolio through its indirect subsidiary, Aegerion Pharmaceuticals, Inc., which includes MYALEPT® and JUXTAPID®, and is also developing zuretinol acetate for the potential treatment of inherited retinal disease caused by underlying mutations in RPE65 or LRAT genes. The company seeks to advance its portfolio of rare disease therapies by investing in science and clinical development.
CONTACT:
Amanda Murphy, Director, Investor Relations & Corporate Communications
Novelion Therapeutics
857-242-5024
amanda.murphy@novelion.com
